Zacks Research Weighs in on AbbVie’s Q1 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Investment analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research report issued on Wednesday, November 20th. Zacks Research analyst S. Ganoria now anticipates that the company will post earnings of $2.62 per share for the quarter, down from their prior forecast of $2.67. The consensus estimate for AbbVie’s current full-year earnings is $10.95 per share. Zacks Research also issued estimates for AbbVie’s Q2 2025 earnings at $3.02 EPS, Q3 2025 earnings at $3.10 EPS, Q4 2025 earnings at $3.25 EPS, FY2025 earnings at $11.98 EPS, Q3 2026 earnings at $3.54 EPS and FY2026 earnings at $13.27 EPS.

ABBV has been the subject of several other research reports. Leerink Partners upgraded AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price objective for the company in a report on Friday. Truist Financial raised their price target on AbbVie from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. William Blair raised shares of AbbVie to a “strong-buy” rating in a research report on Friday, August 30th. UBS Group raised their target price on shares of AbbVie from $195.00 to $200.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Finally, TD Cowen boosted their price target on shares of AbbVie from $195.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $203.50.

AbbVie Stock Performance

AbbVie stock opened at $176.95 on Friday. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The firm has a market cap of $312.70 billion, a P/E ratio of 61.44, a P/E/G ratio of 2.09 and a beta of 0.63. AbbVie has a 1-year low of $137.65 and a 1-year high of $207.32. The firm has a 50-day moving average of $189.47 and a 200-day moving average of $181.17.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.92 by $0.08. The company had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.95 EPS.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be given a $1.64 dividend. The ex-dividend date is Wednesday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a yield of 3.71%. AbbVie’s dividend payout ratio is 215.28%.

Institutional Trading of AbbVie

A number of institutional investors and hedge funds have recently modified their holdings of ABBV. International Assets Investment Management LLC raised its stake in AbbVie by 1,745.0% during the 3rd quarter. International Assets Investment Management LLC now owns 4,728,063 shares of the company’s stock valued at $933,698,000 after buying an additional 4,471,806 shares during the last quarter. Swedbank AB purchased a new stake in AbbVie during the first quarter valued at $367,372,000. Price T Rowe Associates Inc. MD lifted its holdings in AbbVie by 13.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,744,190 shares of the company’s stock valued at $1,956,518,000 after acquiring an additional 1,291,201 shares during the period. State Street Corp boosted its position in AbbVie by 1.6% in the third quarter. State Street Corp now owns 79,067,935 shares of the company’s stock worth $15,614,329,000 after purchasing an additional 1,267,685 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of AbbVie by 12.8% during the 1st quarter. Janus Henderson Group PLC now owns 10,898,246 shares of the company’s stock valued at $1,984,490,000 after purchasing an additional 1,240,434 shares during the period. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.